Throughout the last ten years, Eximmium’s scientists have established, and constantly improved, a proprietary workplan for the discovery of new target molecules on cancer cells and the simultaneous generation of corresponding high-quality antibodies. This technology utilizes patient-derived material and extracellular vesicles, which are constantly released at high numbers by cancer cells and which represent the relevant parts of these cells perfectly.

With its proprietary platform technology, Eximmium has identified a series of completely new targets on cancer cells and established a large collection of proprietary first-in-class antibodies.